Stock News

AnaptysBio, Inc. (ANAB) Reaches $119.15 After 3.00% Down Move; Dafna Capital Management Has Trimmed Insulet (PODD) Stake

Dafna Capital Management Llc decreased Insulet Corp (PODD) stake by 9.45% reported in 2017Q3 SEC filing. Dafna Capital Management Llc sold 6,000 shares as Insulet Corp (PODD)’s stock declined 7.35%. The Dafna Capital Management Llc holds 57,484 shares with $3.17M value, down from 63,484 last quarter. Insulet Corp now has $4.38 billion valuation. The stock increased 1.01% or $0.75 during the last trading session, reaching $75.25. About 48,101 shares traded. Insulet Corporation (NASDAQ:PODD) has risen 48.83% since February 15, 2017 and is uptrending. It has outperformed by 32.13% the S&P500.

The stock of AnaptysBio, Inc. (NASDAQ:ANAB) is a huge mover today! The stock decreased 4.50% or $5.62 during the last trading session, reaching $119.15. About 141,578 shares traded. AnaptysBio, Inc. (NASDAQ:ANAB) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 7 months negative chart setup for the $2.80B company. It was reported on Feb, 15 by Barchart.com. We have $115.58 PT which if reached, will make NASDAQ:ANAB worth $84.00M less.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $2.80 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

Analysts await Insulet Corporation (NASDAQ:PODD) to report earnings on February, 26. They expect $-0.07 EPS, up 56.25% or $0.09 from last year’s $-0.16 per share. After $-0.04 actual EPS reported by Insulet Corporation for the previous quarter, Wall Street now forecasts 75.00% negative EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *